Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 17.64 USD -4.23% Market Closed
Market Cap: 1.3B USD

Schrodinger Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Schrodinger Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
Interest Income Expense
-$4.1m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Interest Income Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inspire Medical Systems Inc
NYSE:INSP
Interest Income Expense
$18.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Interest Income Expense
$36m
CAGR 3-Years
N/A
CAGR 5-Years
89%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Interest Income Expense
$17.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Waystar Holding Corp
NASDAQ:WAY
Interest Income Expense
-$146.3m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry. Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.

SDGR Intrinsic Value
17.67 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Schrodinger Inc's Interest Income Expense?
Interest Income Expense
-4.1m USD

Based on the financial report for Sep 30, 2025, Schrodinger Inc's Interest Income Expense amounts to -4.1m USD.

What is Schrodinger Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
28%

The average annual Interest Income Expense growth rates for Schrodinger Inc have been 28% over the past three years .

Back to Top